The Latest Analyst Ratings for Stevanato Group
Over the past 3 months, 4 analysts have published their opinion on Stevanato Group (NYSE:STVN) stock. These analysts…
Morgan Stanley Maintains Overweight on Stevanato Group, Raises Price Target to $27
Morgan Stanley analyst Drew Ranieri maintains Stevanato Group (NYSE:STVN) with a Overweight and raises the price target from $22 to $27.
Citigroup Maintains Buy on Stevanato Group, Raises Price Target to $30
Citigroup analyst Patrick Donnelly maintains Stevanato Group (NYSE:STVN) with a Buy and raises the price target from $22 to $30.
Earnings Scheduled For March 2, 2023
Companies Reporting Before The Bell
• argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
Stevanato Group Collaborates With Transcoject To Provide Pre-Fillable Syringe Polymer Options For Pharma
Leading drug containment provider to release a unique offering including both COP and COC pre-fillable syringes (PFS), adding to its existing glass PFS portfolio, providing customers with the broadest choice for
Morgan Stanley Maintains Overweight on Stevanato Group, Lowers Price Target to $22
Morgan Stanley analyst Drew Ranieri maintains Stevanato Group (NYSE:STVN) with a Overweight and lowers the price target from $23 to $22.
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Stevanato Group And DWK Life Sciences Sign Non-Exclusive Distribution Agreement For EZ-fill Platform Products
Stevanato Group aims to expand distribution of EZ-fill® whose proven advantages have turned its processing technology into an industry standard for Ready-To-Use products.
Stevanato Group S.p.A. (NYSE:STVN), a
Bexson Biomedical and Stevanato Group Announced Wednesday Award of PDA Drug Delivery Innovation Award
Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced Bexson and Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and
Stevanato Group to Present Recent Developments in Its Integrated Product and Service Offering at Four Major Pharmaceutical Industry Trade Shows Between the U.s. And Europe
Stevanato Group S.p.A. (NYSE: STVN) will be exhibiting at four major international trade shows during the fall season to present its products and services for CMOs, CDMOs and pharma companies.